The present disclosure, among other things, provides new technologies for preparation of medical isotope labeled metal(loid) chalcogen nanoparticles for use in medical imaging and/or therapeutic applications. Provided technologies show a number of advantages as compared with previously available options for preparing and utilizing medical isotopes, including, for example, they utilize metal(loid) chalcogen nanoparticles that serve as universal binders (e.g., via covalent or non-covalent (e.g., chelate) bonds) for medical isotopes to provide medical isotope labeled metal(loid) chalcogen nanoparticles. Surprisingly, the same metal(loid) chalcogen nanoparticles may be used to bind (e.g., covalent or non-covalent e.g., chelation) bonding) a wide variety of different useful medical isotopes without the use of traditional chelating agents.

The present invention comprises: an electron beam accelerator (2); a container (4) housing a raw material (3) for radioactive nuclide production, said raw material including molybdenum 100; a heating device (5) that heats the raw material (3) for radioactive nuclide production; an adsorbent (81) that adsorbs technetium compounds including technetium 99m generated by the heated raw material (3) for radioactive nuclide production; an eluent supply device (10) that supplies an eluent (L1) that causes elution of the technetium compound adsorbed to the adsorbent (81); and a drug recovery unit (13) that recovers the eluent (L2).

The present invention relates to formulations of radiolabelled compounds that are of use in radiotherapy and diagnostic imaging.

The invention provides a compound having the following structure:

D-DT-R,

wherein D is a dextran molecule or a charged dextran molecule having a molecular weight between about 50,000 and about 110,000 Daltons, DT is dodecane tetra-acetic acid (DOTA) or a conjugate base thereof, and R is a radioactive isotope. The invention also provides a method for treating body cavity cancer in a patient afflicted therewith, comprising administering an effective amount of a dextran—dodecane tetraacetic acid—radioactive isotope compound in a pharmaceutically effective vehicle.

The present invention relates to various compositions and methods of using these compositions for imaging natriuretic peptide receptors using, for example, positron emission tomography.

Provided herein are methods for decreasing the toxicity of advanced ablative cancer therapies on neighboring organs. The methods herein provide spacing between single or multiple tumor cites and immediate healthy organs while maintaining or increasing patient quality of life. Such toxicity isolation can be performed by inserting a spacer around the one or more tumor cites, which can be performed concurrently with fiducial marker placement.

Disclosed herein is a benzene ring-containing glucose derivative of formula (I):

##STR00001##

, where R.sub.1 is each independently

##STR00002##

and R.sub.2 is hydrogen. This application also provides a radioactive drug, including a complex formed by the benzene ring-containing glucose derivative and a radionuclide. Use of the benzene ring-containing glucose derivative in the tumor treatment and diagnosis is further provided.

The present disclosure provides a method and an apparatus for producing astatine-211 from alpha-particle bombardment of bismuth-209. The disclosure also relates to a method and apparatus of producing other radionuclides from target nuclides. The apparatus includes a plate having a recessed portion. The recessed portion has a generally inert surface of ceramic or metal, preferably aluminium oxide that does not react with molten bismuth. A bismuth target is placed in the recessed portion and held therein by a foil cover. The foil has a melting temperature greater than target nuclide (i.e., for bismuth, >271° C.). The foil and target nuclide are held in the recessed portion by a cover that is fastened over the foil. The cover has an aperture to allow a beam of radiation, such as alpha particles, from a cyclotron or other accelerator to pass through the cover to the foil and target nuclide.

The disclosure pertains to a strontium-90 sealed radiological or radioactive source, such as may be used with treatment of the eye or other medical or industrial processes. The sealed radiological source includes a radiological insert within an encapsulation. The encapsulation may include increased shielding in the center thereof.

Disclosed is a method of producing Tc-99m by using nuclear resonance fluorescence. More specifically, and a method of preparing Tc-99m by using nuclear resonance fluorescence includes irradiating a ground-state Tc-99 nucleus with a photon beam, thereby causing a nuclear transmutation to proceed such that the nucleus excited to high energy and then undergoes a transition to Tc-99m.